[Treating hypercholesterolemia - when and how]

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypercholesterolemia significantly increases cardiovascular event risk, necessitating effective lipid-lowering strategies.
• Familial hypercholesterolemia represents a high-risk condition requiring early and substantial LDL-cholesterol reduction.
• Novel therapeutic agents are expanding treatment options for managing high cholesterol levels.

Purpose of the Study:

• To review the therapeutic potential of novel agents for hypercholesterolemia management.
• To discuss the mechanisms of action and implications of Lomitapide and PCSK9-inhibitors.
• To evaluate the role of these new agents in risk-adapted cardiovascular prevention.

Main Methods:

• Review of recently approved medications for hypercholesterolemia.
• Analysis of mechanisms of action for MTP-inhibitors and PCSK9-inhibitors.
• Discussion of ongoing and future clinical trial requirements.

Main Results:

• Lomitapide inhibits MTP, reducing LDL-cholesterol independently of LDL-receptors.
• PCSK9-inhibitors block LDL-receptor degradation, increasing LDL-cholesterol clearance.
• Both agents show promise in lowering LDL-cholesterol levels.

Conclusions:

• Novel agents like Lomitapide and PCSK9-inhibitors offer promising new avenues for hypercholesterolemia treatment.
• Further research is needed to confirm long-term safety and cardiovascular event reduction.
• These agents are expected to enhance risk-adapted therapy, used alone or with existing treatments.